康宁胶囊联合拉米夫定治疗慢性乙型肝炎的疗效

EFFICACY OF KANG NING CAPSULE PLUS LAMIVUDINE COMBINATION FOR HBEAG POSITIVE CHRONIC HEPATITIS B PATIENTS

目的观察康宁胶囊联合拉米夫定治疗慢性乙型肝炎(CHB)的临床疗效。方法将CHB患者分为康宁胶囊组、拉米夫定两药联合组共三组,治疗后6、12个月时,分别检测肝功能、血清肝纤维化指标和HBV病毒指标等,进行疗效评价。结果联合组治疗6、12个月时ALT、AST复常率分别为80.0%、87.5%和77.5%、87.5%,显著高于单药组;治疗6个月时,三组HA、LN、PIIIP、IV-C等肝纤维化指标均有明显下降,联用组下降更明显;治疗12个月时,联用组HBeAg转阴率、HBeAg/HBeAb转换率和HBV DNA转阴率分别为42.5%、30.0%、82.5%,HBV DNA转阴率显著高于单药组。结论康宁胶囊联用拉米夫定治疗,可提高HBeAg阳性CHB患者抗病毒的应答率和肝功能改善率,提高临床疗效。

Objective To investigate the efficacy of Kang Ning Capsule in combination with lamivudine（LAM） for therapy of HBeAg positive chronic hepatitis B（CHB）. Methods The eligible patients with HBeAg positive CHB were split into 3 cohorts： one was treated with combination of Kang Ning Capsule plus LAM,the two others with Kang Ning Capsule or LAM monotherapy.The effect was evaluated according to the liver functions,fibrosis indices together with HBV DNA level at 0,6,12 months,respectively. Results The rates of ALT and AST normalization amounted to 80.0% 、87.5% and 77.5% 、87.5% in combination therapy cohort,which were significantly higher than that of monotherapy cohort at 6,12 months.And the fibrosis indices including HA,LN,PIIIP,IV-C had obvious improvement in 3 groups,moreover the rate was higher in combination therapy group than in monotherapy group at month 6.Furthermore,the clearance,seroconversion of HBeAg and HBV DNA undetectable rate was 42.5%,30.0% and 82.5% respectively in combination therapy group,which were also greater than in monotherapy group at month 12. Conclusion Present study suggests that Kang Ning Capsule plus LAM combination therapy was more efficacious than LAM or Kang Ning capsule monotherapy in HBeAg positive CHB patients.